Biotest AG
Biotest AG: Biotest informs about limited availability of albumin
DGAP-News: Biotest AG / Key word(s): Development of Sales / Biotest informs about limited availability of albumin – Due to an equipment failure the availability of albumin is currently limited – Consequences on sales and annual results are currently not assessable
Dreieich, 13 April 2017 Today, Biotest has started to inform its customers about an expected albumin supply shortage within the coming months. This is due to an equipment failure in the production of an albumin intermediate. The equipment failure has already been fixed. In accordance with the relevant authorities, Biotest decided today that all batches which have been produced in the affected equipment and have already been supplied, must not be used until the issue is clarified. Additional necessary analyses are currently conducted. We expect results within the next four weeks. Biotest will take further steps on the basis of these analysis data. The impact on sales and annual results for the Biotest Group are only assessable afterwards. About Human Albumin About Biotest IR contact Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer
13.04.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Biotest AG |
Landsteinerstraße 5 | |
63303 Dreieich | |
Germany | |
Phone: | 0 61 03 – 8 01-0 |
Fax: | 0 61 03 – 8 01-150 |
E-mail: | investor_relations@biotest.de |
Internet: | http://www.biotest.de |
ISIN: | DE0005227235, DE0005227201 |
WKN: | 522723, 522720 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |